AI Article Synopsis
- A new desulfonylation method has been created for tosyl amides using visible light to promote the breaking of N-S bonds.
- This method is efficient and allows for a wide variety of substrates and functional groups to be used.
- It also produces excellent yields, making it a promising advancement in the field of chemistry.
Article Abstract
All lit up: A novel and efficient desulfonylation method of tosyl amides has been developed by means of visible-light-promoted reductive cleavage of N-S bonds. This method has a broad substrate scope, good functional group tolerance, and excellent yields.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/asia.201300224 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antiviral and Immunomodulatory Effects of Zafirlukast Against Flaviviruses via Inhibition of the TNF Signaling Pathway.
J Med Virol
January 2025
Infection and Immunity Research Strength, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Selangor, Malaysia.
The two most clinically important members of the flavivirus genus, Zika virus (ZIKV) and dengue virus (DENV) pose a significant public health challenge. They cause a range of diseases in humans, from hemorrhagic to neurological manifestations, leading to economic and social burden worldwide. Nevertheless, there are no approved antiviral drugs to treat these infections.
View Article and Find Full Text PDFPatient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 study.
Signal Transduct Target Ther
December 2024
Department of Urology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
The randomized phase 3 CHART trial (NCT03520478) revealed that rezvilutamide (REZ) plus androgen deprivation therapy (ADT) in high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC) significantly enhanced radiographic progression-free and overall survival than bicalutamide (BIC)-ADT. Accordingly, we examined patient-reported outcomes (PROs) results, which were exploratory endpoints in the CHART trial. The patients were randomly allocated to receive REZ-ADT or BIC-ADT in a 1:1 ratio.
View Article and Find Full Text PDFTrends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer.
Cancer Med
December 2024
Department of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.
Objective: We aimed to examine trends in novel antiandrogen receptor signal inhibitor (ARSI) usage and medical costs by collecting real-world big data included in The National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) Open Data, covering most of the clinical practices throughout Japan.
Methods: Usage data for outpatient prescriptions from 2016 to 2021 were extracted from the NDB Open Data. Among the 459,610 million tablets/capsules prescribed, prostate cancer-specific agents (bicalutamide, estramustine phosphate, flutamide, abiraterone, enzalutamide, apalutamide, and darolutamide) were selected to investigate the trends of usage and medical costs.
Combined systemic treatments in two patients with ductal salivary carcinoma.
Medicina (B Aires)
December 2024
Departamento de Clínica Oncológica, Instituto de Oncología Ángel H. Roffo, Buenos Aires, Argentina.
Ductal carcinomas, a variant of salivary gland cancer, are characterized by concurrent androgen receptor (AR) positivity and overexpression of HER2, making them potential targets for tailored therapies extensively explored in literature. We present two consecutive cases of patients diagnosed with inoperable metastatic ductal carcinoma, both displaying HER2 overexpression and AR positivity, who underwent combination therapy involving chemotherapy and dual targeted agents. Both patients diagnosed with centralized inoperable ductal carcinoma were retrospectively analyzed and received trastuzumab, docetaxel, leuprolide and bicalutamida as first-line therapy until progression, defined by RECIST criteria.
View Article and Find Full Text PDFEfficacy and safety of remimazolam tosylate for patients undergoing off-pump coronary artery bypass grafting: a study protocol for a non-inferiority randomised controlled trial in China.
BMJ Open
November 2024
Department of Anaesthesiology, Zibo Central Hospital, Zibo, Shandong, China
Introduction: Maintaining haemodynamic stability is crucial but challenging during the induction and maintenance of general anaesthesia (GA) in patients undergoing off-pump coronary artery bypass grafting (OPCABG). Remimazolam tosylate is a novel ultra-short-acting benzodiazepine with minimal cardiovascular depression. Currently, non-inferior studies comparing the haemodynamic changes induced by remimazolam and etomidate are limited.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!